Developer docs
API playgroundTry for free, no card

Search company profiles

Precigen

Full company profile

uuid0000frz

Namestring
Precigen
Legal namestring
Precigen, Inc.
Websiteurl
precigen.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Precigen is a commercial-stage biopharmaceutical company headquartered in Germantown, Maryland, that develops precision immunotherapies and gene therapies for rare diseases and oncology. Following FDA approval of PAPZIMEOS in August 2025, the company transitioned from clinical-stage to commercial-stage operations. PAPZIMEOS (zopapogene imadenovec-drba) is the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP), a rare chronic respiratory disease caused by HPV types 6 or 11 that affects approximately 27,000 adults in the US and over 170,000 worldwide. The pipeline extends the same platforms into oncology: PRGN-2009 for HPV-associated cancers (in combination with pembrolizumab), PRGN-3006 for acute myeloid leukemia and higher-risk myelodysplastic syndromes, PRGN-3005 for ovarian cancer, and PRGN-3007 for hematological and solid tumors.

The pipeline is built on two proprietary technology platforms. AdenoVerse is a library of gorilla adenovectors featuring up to 12 kb payload capacity, low seroprevalence enabling repeat administration, and scalable manufacturing. UltraCAR-T is a non-viral CAR-T platform using the Sleeping Beauty transposon system that enables overnight autologous manufacturing (versus weeks for conventional CAR-T), expresses multiple genes simultaneously (antigen-specific CAR, kill switch, and membrane-bound IL-15), and includes a proprietary kill switch for selective elimination of the cell therapy in vivo. Supporting technologies include UltraVector for computational DNA construction, the licensed Sleeping Beauty system, AttSite recombinases, and the UltraPorator high-throughput semi-closed electroporation system.

Precigen generates revenue from commercial sales of PAPZIMEOS, priced at approximately $460,000 per four-dose patient regimen. Q1 2026 net product revenue reached $21.6 million, up from $3.4 million in Q4 2025 (the first partial quarter of launch), and total Q1 2026 revenue of $23.25 million exceeded the $20.8 million forecast. Distribution runs through direct physician and hospital channels with field sales led by Chief Commercial Officer Phil Tennant, supported by an Eversana-partnered patient hub for enrollment. Payer coverage spans approximately 297 million US lives, and a permanent J-code (J3404) effective April 2026 streamlines Medicare and Medicaid reimbursement. Precigen is publicly listed on NASDAQ under ticker PGEN, has 101-250 employees, and is led by President and CEO Helen Sabzevari, PhD, with Randal J. Kirk as Executive Chairman. The company has raised $184 million across public and private rounds in 2023-2024, secured a $100 million non-dilutive credit facility from Pharmakon Advisors in September 2025, and projects cash flow break-even by the end of 2026.

Short descriptiontext

Precigen is a commercial-stage biopharmaceutical company developing precision immunotherapies on its proprietary AdenoVerse and UltraCAR-T platforms, primarily serving adults with recurrent respiratory papillomatosis via FDA-approved PAPZIMEOS and pursuing an oncology pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersGermantown, United States
HQ citystring
Germantown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy platforms, cell therapy manufacturing, immunotherapy products, rare disease treatments, adenoviral vector technology
Industry4 codes
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1PAPZIMEOS Product Sales
TypeOne Time License
Description

Revenue from commercial sales of PAPZIMEOS (zopapogene imadenovec-drba), FDA-approved immunotherapy for recurrent respiratory papillomatosis. Product launched August 2025 with Q4 2025 revenue of $3.4M and Q1 2026 revenue of $21.6M. Revenue trajectory showing strong acceleration with projected cash flow break-even by end of 2026.

prnewswire.com
2Non-Dilutive Financing
TypeTransaction Fee
Description

$100 million credit facility from Pharmakon Advisors to support US commercialization of PAPZIMEOS and potential international expansion including pediatric and HPV-related indications.

prnewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details1 tier
1PAPZIMEOS four-dose treatment regimen
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Approximately $460,000 per patient for complete four-dose treatment course

finance.yahoo.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1PAPZIMEOS
Description

PAPZIMEOS (zopapogene imadenovec-drba) is the company's FDA-approved immunotherapy for recurrent respiratory papillomatosis (RRP), the first and only approved treatment for adults with this rare disease.

precigen.com
Core offering1 text field

Precigen is a commercial-stage biopharmaceutical company that develops and sells precision gene and cell therapies, with its flagship approved product PAPZIMEOS (zopapogene imadenovec-drba) being the first and only FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis (RRP). The company leverages two proprietary technology platforms—AdenoVerse (gorilla adenovectors) and UltraCAR-T (non-viral cell therapy)—to manufacture and commercialize therapeutics in immuno-oncology, autoimmune disorders, and infectious diseases, and is advancing a clinical pipeline including PRGN-2009 for HPV-associated cancers and UltraCAR-T candidates for AML, MDS, and ovarian cancer.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 83% of complete responders (15/18) maintained ongoing complete responses for at least 36 months without additional treatment
+5 more records
Product overview1 text field

Precigen is a commercial-stage biopharmaceutical company with an approved product (PAPZIMEOS) and multiple pipeline candidates built on two core technology platforms: AdenoVerse (adenoviral vectors for immunotherapy) and UltraCAR-T (cell therapy using non-viral gene delivery). PAPZIMEOS, approved in August 2025, is the first FDA-approved immunotherapy for adult RRP and is now commercially available. The pipeline includes PRGN-2009 for HPV-associated cancers, and three UltraCAR-T candidates (PRGN-3006 for AML/MDS, PRGN-3005 for ovarian cancer, and PRGN-3007 for hematological and solid tumors). Supporting technology platforms include UltraVector for DNA construction, the Sleeping Beauty non-viral delivery system, AttSite recombinases, and UltraPorator electroporation equipment.

Product and service5 records
1PAPZIMEOS (zopapogene imadenovec-drba)
CategoryApproved Biopharmaceutical Product
Description

FDA-approved subcutaneous immunotherapy treatment (5×10^11 PU/mL) for recurrent respiratory papillomatosis (RRP) in adults, the first and only approved therapy addressing the root cause of RRP, an HPV 6/11-associated rare disease affecting approximately 27,000 adults in the US. Priced at approximately $460,000 per patient for a four-dose treatment regimen.

2PRGN-2009
CategoryPipeline Biopharmaceutical Candidate
Description

AdenoVerse platform-based investigational HPV immunotherapy in clinical development for HPV-associated cancers, currently being evaluated in combination with pembrolizumab in clinical trials.

3PRGN-3006 UltraCAR-T
CategoryPipeline Biopharmaceutical Candidate
Description

Investigational UltraCAR-T cell therapy for acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS), utilizing non-viral gene delivery with overnight manufacturing process.

4PRGN-3005 UltraCAR-T
CategoryPipeline Biopharmaceutical Candidate
Description

Investigational UltraCAR-T cell therapy for ovarian cancer utilizing non-viral multigenic delivery with rapid overnight manufacturing.

5PRGN-3007 UltraCAR-T
CategoryPipeline Biopharmaceutical Candidate
Description

Investigational UltraCAR-T cell therapy for hematological and solid tumors, incorporating intrinsic checkpoint inhibition for improved anti-tumor activity.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-11
Description

Continued collaboration to recognize International RRP Awareness Day on June 11, 2026 (third annual). Partnership focuses on amplifying patient and community voices through online hub rrpawareness.org. Foundation sponsored expert consensus paper recommending PAPZIMEOS as new standard of care published in The Laryngoscope.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-05-26
Description

Partnership for commercialization support including patient hub services and market access. Company presented at Eversana-hosted Biotech Showcase event alongside J.P. Morgan Healthcare Conference.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-10-26
Description

Presented Phase I clinical data on investigational UltraCAR-T products at Second Bone Marrow Transplant and Cellular Therapy Congress sponsored by ADSCC in Abu Dhabi.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage gene therapy company with an approved product (VYJUVEK) for a rare disease (DEB), similar in scale and trajectory to Precigen. Closely comparable as a small-cap gene therapy for rare diseases with a single approved asset driving commercial revenue.

TypeDirect peer
Description

Commercial-stage cell therapy company with FDA-approved Amtagvi for melanoma and lifileucel pipeline, addressing solid tumors through autologous cell therapy. Comparable in stage, scale, and focus on cell-based immuno-oncology platforms.

TypeDirect peer
Description

Allogeneic T-cell immunotherapy company developing cell therapies for cancers and viral diseases. Comparable in cell-therapy platform approach and indication overlap in HPV-associated disease.

TypeDirect peer
Description

TCR-T cell therapy company focused on solid tumors, including HPV-associated cancers. Comparable cell-therapy platform overlap and oncology indication set.

TypeDirect peer
Description

Allogeneic CAR-T cell therapy developer using non-viral gene editing approaches. Comparable cell-therapy platform focus and pursuit of next-generation CAR-T manufacturing.

6bluebird bio
TypeDirect peer
Description

Gene therapy company focused on rare diseases with multiple approved products (Zynteglo, Skysona, Lyfgenia). Highly comparable as a small-cap gene therapy for rare diseases navigating commercial launch.

TypeBroad incumbent
Description

Established commercial-stage gene therapy leader in rare diseases (Elevidys for DMD, Exondys 51). Comparable gene therapy for rare diseases but at a much larger scale and broader pipeline.

TypeEmerging player
Description

Gene-editing therapy company with Casgevy approved for sickle cell disease. Comparable in gene-based therapy platforms for rare diseases and adjacent oncology applications.

TypeBroad incumbent
Description

Established rare disease biotech with a portfolio of approved biologics and gene therapies (e.g., Roctavian for hemophilia A). Comparable rare-disease commercial focus but at significantly larger scale.

TypeDirect peer
Description

Commercial-stage rare disease company developing biologics and gene therapies, including Crysvita and Dojolvi. Comparable rare disease therapeutic focus and small/mid-cap commercial stage.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A8 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Precigen

Biopharmaceuticalsprecigen.com

Precigen is a commercial-stage biopharmaceutical company developing precision immunotherapies on its proprietary AdenoVerse and UltraCAR-T platforms, primarily serving adults with recurrent respiratory papillomatosis via FDA-approved PAPZIMEOS and pursuing an oncology pipeline.

What Precigen does

Precigen is a commercial-stage biopharmaceutical company headquartered in Germantown, Maryland, that develops precision immunotherapies and gene therapies for rare diseases and oncology. Following FDA approval of PAPZIMEOS in August 2025, the company transitioned from clinical-stage to commercial-stage operations. PAPZIMEOS (zopapogene imadenovec-drba) is the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP), a rare chronic respiratory disease caused by HPV types 6 or 11 that affects approximately 27,000 adults in the US and over 170,000 worldwide. The pipeline extends the same platforms into oncology: PRGN-2009 for HPV-associated cancers (in combination with pembrolizumab), PRGN-3006 for acute myeloid leukemia and higher-risk myelodysplastic syndromes, PRGN-3005 for ovarian cancer, and PRGN-3007 for hematological and solid tumors.

The pipeline is built on two proprietary technology platforms. AdenoVerse is a library of gorilla adenovectors featuring up to 12 kb payload capacity, low seroprevalence enabling repeat administration, and scalable manufacturing. UltraCAR-T is a non-viral CAR-T platform using the Sleeping Beauty transposon system that enables overnight autologous manufacturing (versus weeks for conventional CAR-T), expresses multiple genes simultaneously (antigen-specific CAR, kill switch, and membrane-bound IL-15), and includes a proprietary kill switch for selective elimination of the cell therapy in vivo. Supporting technologies include UltraVector for computational DNA construction, the licensed Sleeping Beauty system, AttSite recombinases, and the UltraPorator high-throughput semi-closed electroporation system.

Precigen generates revenue from commercial sales of PAPZIMEOS, priced at approximately $460,000 per four-dose patient regimen. Q1 2026 net product revenue reached $21.6 million, up from $3.4 million in Q4 2025 (the first partial quarter of launch), and total Q1 2026 revenue of $23.25 million exceeded the $20.8 million forecast. Distribution runs through direct physician and hospital channels with field sales led by Chief Commercial Officer Phil Tennant, supported by an Eversana-partnered patient hub for enrollment. Payer coverage spans approximately 297 million US lives, and a permanent J-code (J3404) effective April 2026 streamlines Medicare and Medicaid reimbursement. Precigen is publicly listed on NASDAQ under ticker PGEN, has 101-250 employees, and is led by President and CEO Helen Sabzevari, PhD, with Randal J. Kirk as Executive Chairman. The company has raised $184 million across public and private rounds in 2023-2024, secured a $100 million non-dilutive credit facility from Pharmakon Advisors in September 2025, and projects cash flow break-even by the end of 2026.

Precigen firmographics

Firmographics
Name
Precigen
Legal name
Precigen, Inc.
Website
https://precigen.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
Precigen is a commercial-stage biopharmaceutical company developing precision immunotherapies on its proprietary AdenoVerse and UltraCAR-T platforms, primarily serving adults with recurrent respiratory papillomatosis via FDA-approved PAPZIMEOS and pursuing an oncology pipeline.
Ownership category
akta.pro rank

Precigen industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Gene therapy platforms
  • Cell therapy manufacturing
  • Immunotherapy products
  • Rare disease treatments
  • Adenoviral vector technology

Where Precigen is headquartered

Location

Headquarters

HQ city
Germantown
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Precigen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. PAPZIMEOS Product Sales: Revenue from commercial sales of PAPZIMEOS (zopapogene imadenovec-drba), FDA-approved immunotherapy for recurrent respiratory papillomatosis. Product launched August 2025 with Q4 2025 revenue of $3.4M and Q1 2026 revenue of $21.6M. Revenue trajectory showing strong acceleration with projected cash flow break-even by end of 2026.
  2. Non-Dilutive Financing: $100 million credit facility from Pharmakon Advisors to support US commercialization of PAPZIMEOS and potential international expansion including pediatric and HPV-related indications.

Pricing tiers

ModelBillingPrice
Unit PricingMulti-year contractPAPZIMEOS four-dose treatment regimen

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Precigen product offering

Product offering

Core offering

Precigen is a commercial-stage biopharmaceutical company that develops and sells precision gene and cell therapies, with its flagship approved product PAPZIMEOS (zopapogene imadenovec-drba) being the first and only FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis (RRP). The company leverages two proprietary technology platforms—AdenoVerse (gorilla adenovectors) and UltraCAR-T (non-viral cell therapy)—to manufacture and commercialize therapeutics in immuno-oncology, autoimmune disorders, and infectious diseases, and is advancing a clinical pipeline including PRGN-2009 for HPV-associated cancers and UltraCAR-T candidates for AML, MDS, and ovarian cancer.

Product overview

Precigen is a commercial-stage biopharmaceutical company with an approved product (PAPZIMEOS) and multiple pipeline candidates built on two core technology platforms: AdenoVerse (adenoviral vectors for immunotherapy) and UltraCAR-T (cell therapy using non-viral gene delivery). PAPZIMEOS, approved in August 2025, is the first FDA-approved immunotherapy for adult RRP and is now commercially available. The pipeline includes PRGN-2009 for HPV-associated cancers, and three UltraCAR-T candidates (PRGN-3006 for AML/MDS, PRGN-3005 for ovarian cancer, and PRGN-3007 for hematological and solid tumors). Supporting technology platforms include UltraVector for DNA construction, the Sleeping Beauty non-viral delivery system, AttSite recombinases, and UltraPorator electroporation equipment.

Differentiator

Problem solved

Functional benefit

Brands

  • PAPZIMEOS: PAPZIMEOS (zopapogene imadenovec-drba) is the company's FDA-approved immunotherapy for recurrent respiratory papillomatosis (RRP), the first and only approved treatment for adults with this rare disease.

Products and services

  • PAPZIMEOS (zopapogene imadenovec-drba) FDA-approved subcutaneous immunotherapy treatment (5×10^11 PU/mL) for recurrent respiratory papillomatosis (RRP) in adults, the first and only approved therapy addressing the root cause of RRP, an HPV 6/11-associated rare disease affecting approximately 27,000 adults in the US. Priced at approximately $460,000 per patient for a four-dose treatment regimen.
  • PRGN-2009 AdenoVerse platform-based investigational HPV immunotherapy in clinical development for HPV-associated cancers, currently being evaluated in combination with pembrolizumab in clinical trials.
  • PRGN-3006 UltraCAR-T Investigational UltraCAR-T cell therapy for acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS), utilizing non-viral gene delivery with overnight manufacturing process.
  • PRGN-3005 UltraCAR-T Investigational UltraCAR-T cell therapy for ovarian cancer utilizing non-viral multigenic delivery with rapid overnight manufacturing.
  • PRGN-3007 UltraCAR-T Investigational UltraCAR-T cell therapy for hematological and solid tumors, incorporating intrinsic checkpoint inhibition for improved anti-tumor activity.

Quantifiable outcome

  • 83% of complete responders (15/18) maintained ongoing complete responses for at least 36 months without additional treatment
  • +5 more outcomes

Companies that use Precigen

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Precigen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Precigen partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Recurrent Respiratory Papillomatosis Foundation (RRPF)coreStrategic or Co-development Partner · 11 June 2026Continued collaboration to recognize International RRP Awareness Day on June 11, 2026 (third annual). Partnership focuses on amplifying patient and community voices through online hub rrpawareness.org. Foundation sponsored expert consensus paper recommending PAPZIMEOS as new standard of care published in The Laryngoscope.
  • EversanacoreGTM or Marketing Partner · 26 May 2026Partnership for commercialization support including patient hub services and market access. Company presented at Eversana-hosted Biotech Showcase event alongside J.P. Morgan Healthcare Conference.
  • Abu Dhabi Stem Cells Center (ADSCC)minorStrategic or Co-development Partner · 26 October 2024Presented Phase I clinical data on investigational UltraCAR-T products at Second Bone Marrow Transplant and Cellular Therapy Congress sponsored by ADSCC in Abu Dhabi.

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Precigen competitors and assessment

Company assessment

Direct peers

  • Krystal Biotech: Commercial-stage gene therapy company with an approved product (VYJUVEK) for a rare disease (DEB), similar in scale and trajectory to Precigen. Closely comparable as a small-cap gene therapy for rare diseases with a single approved asset driving commercial revenue.
  • Iovance Biotherapeutics: Commercial-stage cell therapy company with FDA-approved Amtagvi for melanoma and lifileucel pipeline, addressing solid tumors through autologous cell therapy. Comparable in stage, scale, and focus on cell-based immuno-oncology platforms.
  • Atara Biotherapeutics: Allogeneic T-cell immunotherapy company developing cell therapies for cancers and viral diseases. Comparable in cell-therapy platform approach and indication overlap in HPV-associated disease.
  • Adaptimmune Therapeutics: TCR-T cell therapy company focused on solid tumors, including HPV-associated cancers. Comparable cell-therapy platform overlap and oncology indication set.
  • Allogene Therapeutics: Allogeneic CAR-T cell therapy developer using non-viral gene editing approaches. Comparable cell-therapy platform focus and pursuit of next-generation CAR-T manufacturing.
  • bluebird bio: Gene therapy company focused on rare diseases with multiple approved products (Zynteglo, Skysona, Lyfgenia). Highly comparable as a small-cap gene therapy for rare diseases navigating commercial launch.
  • Ultragenyx Pharmaceutical: Commercial-stage rare disease company developing biologics and gene therapies, including Crysvita and Dojolvi. Comparable rare disease therapeutic focus and small/mid-cap commercial stage.

Broad incumbents

  • Sarepta Therapeutics: Established commercial-stage gene therapy leader in rare diseases (Elevidys for DMD, Exondys 51). Comparable gene therapy for rare diseases but at a much larger scale and broader pipeline.
  • BioMarin Pharmaceutical: Established rare disease biotech with a portfolio of approved biologics and gene therapies (e.g., Roctavian for hemophilia A). Comparable rare-disease commercial focus but at significantly larger scale.

Emerging players

  • CRISPR Therapeutics: Gene-editing therapy company with Casgevy approved for sickle cell disease. Comparable in gene-based therapy platforms for rare diseases and adjacent oncology applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Precigen social profiles

Digital presence

Precigen compliance and trust

Trust signal

Compliance1 record

Precigen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Precigen leadership team

Management profile

Number of profiles

Profiles17 records

Precigen funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Precigen M&A and investment

M&A and investment

M&A8 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Precigen

What does Precigen do?

Precigen is a commercial-stage biopharmaceutical company that develops and sells precision gene and cell therapies, with its flagship approved product PAPZIMEOS (zopapogene imadenovec-drba) being the first and only FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis (RRP). The company leverages two proprietary technology platforms—AdenoVerse (gorilla adenovectors) and UltraCAR-T (non-viral cell therapy)—to manufacture and commercialize therapeutics in immuno-oncology, autoimmune disorders, and infectious diseases, and is advancing a clinical pipeline including PRGN-2009 for HPV-associated cancers and UltraCAR-T candidates for AML, MDS, and ovarian cancer.

Is Precigen a public or private company?

Precigen is a public company. It is classified as public and is currently operating.

When was Precigen founded?

Precigen was founded in 2015. It employs 101 to 250 people.

Where is Precigen based?

Precigen is headquartered in Germantown, United States, in the North America region.

How does Precigen make money?

Two revenue lines are on record. PAPZIMEOS Product Sales are the primary driver. The others are non-Dilutive Financing.

Who are Precigen's main competitors?

Direct peers on record are Krystal Biotech, Iovance Biotherapeutics, Atara Biotherapeutics, Adaptimmune Therapeutics, Allogene Therapeutics, bluebird bio and Ultragenyx Pharmaceutical. Broad incumbents are Sarepta Therapeutics and BioMarin Pharmaceutical. CRISPR Therapeutics is listed as an emerging player.

Does Precigen have an API?

No public API is recorded for Precigen.

What industry is Precigen in?

Precigen's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaPrecigen: Upgrading To Buy As Competitive Fears Over VOCERYQ Look OverblownPrecigen upgraded from Hold to Buy, citing VOCERYQ's FDA approval as overstated competition. Q3 net product revenue hit $72.9M, cash flow turned positive, and cash rose to $51M. The stock is attractive below $6.00, with risks including competition and pipeline failures.Simply Wall StWhat Precigen (PGEN)'s Profit Turn Means For ShareholdersPrecigen reported Q3 2026 revenue of US$74.15 million and net income of US$35.77 million, a shift from a loss a year earlier. Nine-month net income rose to US$47.91 million, supporting a transition to stronger earnings. Analysts forecast revenue of US$654.3 million and earnings of US$393.8 million by 2029.Simply Wall StPrecigen (PGEN) Earnings Turnaround Puts Its Valuation Back In FocusPrecigen reported Q3 2026 revenue of $74.15 million and net income of $35.77 million, reversing last year's loss. Its share price fell 39.44% over 30 days despite a 5.82% one-day gain. Analysts value the stock at $13.65, implying a wide gap from the current $4.73 price.American Banking and Market NewsCalamos Advisors LLC Makes New $2.63 Million Investment in Precigen, Inc. $PGENCalamos Advisors acquired a new stake in Precigen, purchasing 307,363 shares valued at approximately $2.63 million in Q3. Precigen reported Q3 revenue of $74.15 million, beating estimates, and EPS of $0.08, above the $0.06 consensus. Analysts have a consensus price target of $13.50.Simply Wall StPrecigen Stock Turns Heads After Q3 Profit SwingPrecigen reported Q3 2026 revenue of $74.15 million and net income of $35.77 million, a shift from a loss a year earlier. Basic EPS was $0.10, and year-to-date revenue reached $152.38 million. Analysts project $654.3 million revenue by 2029, implying a 205% upside.American Banking and Market NewsPrecigen (NASDAQ:PGEN) Stock Rating Raised to Strong-Buy at Wall Street ZenWall Street Zen raised Precigen's rating to strong-buy, while other analysts issued mixed ratings. The company reported Q3 revenue of $74.15 million, up 2,437.6% year-over-year, and EPS of $0.08, beating estimates. Insiders sold 235,000 shares over the last 90 days.Simply Wall StAnalysts Are Updating Their Precigen, Inc. (NASDAQ:PGEN) Estimates After Its Third-Quarter ResultsPrecigen reported Q3 revenue of $74m, 3.6% above expectations, and EPS of $0.08, in line with estimates. Analysts' 2027 revenue and EPS forecasts remained unchanged at $437.1m and $0.62, with a price target of $13.65. The company is expected to grow revenue faster than the industry.TradingViewCitizens maintains Precigen at Market Outperform, raises price target to $12 from $11Citizens maintained Precigen at Market Outperform and raised its price target to $12 from $11, a 9.1% increase. The price target implies an upside of 137.4% from the Nov 4 close of $5.05.Business & FinancialCitizens Raises Papzimeos Sales Forecast After Precigen's Q3 Topline Beat Sees 142% Upside Potential In PGEN StockCitizens raised its price target on Precigen (PGEN) to $12 from $11 after the biotech reported Q3 revenue of $74.1 million, beating estimates. Papzimeos sales hit $72.9 million, exceeding the $60 million forecast, and the company achieved its first cash-flow-positive quarter. Citizens also raised its Q4 sales forecast to $88 million.Seeking AlphaPrecigen, Inc. (PGEN) Q3 2026 Earnings Call TranscriptPrecigen reported its Q3 2026 financial results and business update on November 4, 2026. CEO Helen Sabzevari highlighted the quarter as a defining milestone, and CFO Harry Thomasian discussed financial results. The call included forward-looking statements with risks and uncertainties.